A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy

Sridhar Kamath, Andrew Blann, Bernard Chin, F Lanza, B Aleil, JP Cazenave, Gregory Lip

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

BACKGROUND: Platelet function may be abnormal in patients with atrial fibrillation (AF) and could be related to abnormal thrombogenesis. The aim of this cross-sectional study was to investigate new aspects of platelet biology in AF, predominantly focusing on platelet activation and the effects of concomitant antiplatelet and anticoagulant therapy. PATIENTS AND METHODS: The study group of 238 patients were (i). 93 patients on no antithrombotic therapy, (ii). 60 patients taking 75-325 mg aspirin/day, and (iii). 85 patients on dose-adjusted warfarin (International Normalised Ratio [INR] range 2.0-3.0). Results were compared with those from 50 age- and sex-matched normal subjects. Platelet markers (plasma beta-thromboglobulin, soluble glycoprotein V [both ELISA]), coagulation markers (fibrin D-dimer [ELISA] and fibrinogen [Clauss]), and platelet aggregation in response to standard platelet agonists were studied. RESULTS: beta-thromboglobulin (P=0.01), soluble glycoprotein V (P
Original languageEnglish
Pages (from-to)1788-1795
Number of pages8
JournalEuropean Heart Journal
Volume23
Issue number22
DOIs
Publication statusPublished - 15 Nov 2002

Keywords

  • atrial fibrillation
  • platelets
  • platelet aggregation
  • fibrin D-dimer
  • soluble glycoprotein V
  • betathromboglobulin

Fingerprint

Dive into the research topics of 'A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy'. Together they form a unique fingerprint.

Cite this